
On November 10, 2026, the FDA issued final, nonbinding guidance on validation of in vitro diagnostic products (IVDs) for emergency use under Section 564. The guidance explains how clinical and analytical evidence can support submissions made before an emergency use authorization (EUA).
For IVD developers, the immediate significance is a clearer account of the evidence relevant to an emergency authorization pathway. The FDA’s stated aim is to help accelerate the process while maintaining attention to product safety and effectiveness.

The guidance connects two types of evidence to the preparation of an EUA submission: analytical evidence and clinical evidence. Its value to a developer lies in understanding how those bodies of evidence can support the submission before an authorization decision. This places validation and submission planning close together in the regulatory process.
Because the guidance is nonbinding, its publication should not be read as an automatic authorization for an IVD or as a guarantee that an individual submission will proceed faster. Its practical effect will depend on how the guidance applies to a particular product and the evidence presented in support of that product.
The most direct effects are likely to be felt in the work leading up to an EUA submission. Developers may use the guidance to consider how their analytical and clinical evidence fits the emergency authorization pathway and how that evidence is presented to the FDA. Clearer expectations at this stage could help teams organize their submissions, although the time saved, if any, will depend on the circumstances of each submission.
The distinction between the guidance’s purpose and its results matters. Accelerating the regulatory process is an aim of the guidance; its release alone does not establish a particular review timeline or demonstrate a change in authorization outcomes. Similarly, the emphasis on safety and effectiveness describes the intended balance, rather than a finding about any individual test.
As the guidance is applied, a point to watch is how its explanation of clinical and analytical evidence informs submissions during public health emergencies. Any broader effect on the speed of authorization will depend on its use in practice and on the evidence supporting individual products.
Recommended News
The VitalSync Intelligence Brief
Receive daily deep-dives into MedTech innovations and regulatory shifts.